How do we best balance optimal timing of fdg pet-ct imaging?

Nuclear Medicine Communications

Volumn 28, Issue 12, 2007, Pages 885-887

  Hofman, Michael S ^a   O’Doherty, Michael ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BENIGN TUMOR; CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG EXCRETION; DRUG UPTAKE; EDITORIAL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; TUMOR LOCALIZATION;

FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 37349107851     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282f150b5     Document Type: Editorial

References (24)

1. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996; 56:1164-1167.
2. 3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol 1996; 23:533-541.
3. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42:1412-1417.
4. Kok PJ, van Eerd JE, Boerman OC, Corstens FH, Oyen WJ. Biodistribution and imaging of FDG in rats with LS174T carcinoma xenografts and focal Escherichia coli infection. Cancer Biother Radiopharm 2005; 20:310-315.
5. 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26:22-30.
6. Boerner AR, Weckesser M, Herzog H, Schmitz T, Audretsch W, Nitz U, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999; 26:226-230.
7. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35:1308-1312.
8. Stahl A, Ott K, Schwaiger M, Weber WA. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 2004; 31:1471-1478.
9. Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001; 28:696-703.
10. 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes? Eur J Nucl Med Mol Imaging 2005; 32:541-548.
11. Kuker RA, Mesoloras G, Gulec SA. Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease. Int Semin Surg Oncol 2007; 4:17.
12. 18F-FDG PET for the evaluation of gallbladder carcinoma. Nucl Med 2006; 47:633-638.
13. Sakamoto S, Ishii K, Hosaka K, Mori T, Sasaki M, Mori E. Detectability of hypometabolic regions in mild Alzheimer disease: function of time after the injection of 2-[fluorine 18]-fluoro-2-deoxy-D-glucose. AJNR Am J Neuroradiol 2005; 26:843-847.
14. Nakamoto Y, Saga T, Higashi T, Ishimori T, Kobayashi H, Ishizu K, et al. Optimal scan time for evaluating pancreatic disease with positron emission tomography using F-18-fluorodeoxyglucose. Ann Nucl Med 2003; 17:421-426.
15. Ma SY, See LC, Lai CH, Chou HH, Tsai CS, Ng KK, et al. Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 2003; 44:1775-1783.
16. Yen TC, Ng KK, Ma SY, Chou HH, Tsai CS, Hsueh S, et al. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. J Clin Oncol 2003; 21:3651-3658.
17. Thie JA, Hubner KF, Smith GT. Optimizing imaging time for improved performance in oncology PET studies. Mol Imaging Biol 2002; 4:238-244.
18. 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors. Ann Nucl Med 2006; 20:671-675.
19. Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999; 26:1345-1348.
20. Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, Doi R, Imamura M, et al. Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 2005; 32:389-397.
21. 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 2006; 47:1440-1446.
22. Nitzsche EU, Hoegerle S, Mix M, Brink I, Otte A, Moser E, et al. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nucl Med Mol Imaging 2002; 29:237-242.
23. Xiu Y, Bhutani C, Dhurairaj T, Yu JQ, Dadparvar S, Reddy S, et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med 2007; 32:101-105.
24. Sahlmann CO, Siefker U, Lehmann K, Meller J. Dual time point 2-[18F] fluoro-2′-deoxyglucose positron emission tomography in chronic bacterial osteomyolitis. Nucl Med Commun 2004; 25:819-823.